We published a new article on Seeking Alpha on synthetic cannabinoid pharmaceuticals:
Cannabinoids have proven to have a valuable place in medicine. Unfortunately, marijuana is classified as a Schedule I substance by the DEA.
With Trump's having chosen Alabama Senator Jeff Sessions for Attorney General, many marijuana investors are afraid of what could happen to state-level progress.
We will focus on companies making synthetic cannabinoid-based pharmaceuticals, because they are scheduled differently than traditional marijuana and are certain to weather Sessions' policies.
Read the rest of our article on Seeking Alpha here. Also, don't forget to connect with us on social media using the links to the right of this article.